Literature DB >> 16391015

The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL.

Anthony G Brickner1, Anne M Evans, Jeffrey K Mito, Suzanne M Xuereb, Xin Feng, Tetsuya Nishida, Liane Fairfull, Robert E Ferrell, Kenneth A Foon, Donald F Hunt, Jeffrey Shabanowitz, Victor H Engelhard, Stanley R Riddell, Edus H Warren.   

Abstract

Minor histocompatibility antigens (mHAg's) are peptides encoded by polymorphic genes that are presented by major histocompatibility complex (MHC) molecules and recognized by T cells in recipients of allogeneic hematopoietic cell transplants. Here we report that an alternative transcript of the proliferation-associated nuclear element 1 (PANE1) gene encodes a novel human leukocyte antigen (HLA)-A(*)0301-restricted mHAg that is selectively expressed in B-lymphoid cells. The antigenic peptide is entirely encoded within a unique exon not present in other PANE1 transcripts. Sequencing of PANE1 alleles in mHAg-positive and mHAg-negative cells demonstrates that differential T-cell recognition is due to a single nucleotide polymorphism within the variant exon that replaces an arginine codon with a translation termination codon. The PANE1 transcript that encodes the mHAg is expressed at high levels in resting CD19(+) B cells and B-lineage chronic lymphocytic leukemia (B-CLL) cells, and at significantly lower levels in activated B cells. Activation of B-CLL cells through CD40 ligand (CD40L) stimulation decreases expression of the mHAg-encoding PANE1 transcript and reciprocally increases expression of PANE1 transcripts lacking the mHAg-encoding exon. These studies suggest distinct roles for different PANE1 isoforms in resting compared with activated CD19(+) cells, and identify PANE1 as a potential therapeutic target in B-CLL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16391015      PMCID: PMC1895781          DOI: 10.1182/blood-2005-08-3501

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein.

Authors:  Eric Spierings; Anthony G Brickner; Jennifer A Caldwell; Suzanne Zegveld; Nia Tatsis; Els Blokland; Jos Pool; Richard A Pierce; Sahana Mollah; Jeffrey Shabanowitz; Laurence C Eisenlohr; Peter van Veelen; Ferry Ossendorp; Donald F Hunt; Els Goulmy; Victor H Engelhard
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

2.  Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway.

Authors:  Catherine Kern; Jean-Francois Cornuel; Christian Billard; Ruoping Tang; Danielle Rouillard; Virginie Stenou; Thierry Defrance; Florence Ajchenbaum-Cymbalista; Pierre-Yves Simonin; Sophie Feldblum; Jean-Pierre Kolb
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

Review 3.  Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.

Authors:  Nelson J Chao
Journal:  Biol Blood Marrow Transplant       Date:  2004-04       Impact factor: 5.742

4.  Tnfrsf13c (Baffr) is mis-expressed in tumors with murine leukemia virus insertions at Lvis22.

Authors:  Kathryn E Hentges; Sujatha P Yarlagadda; Monica J Justice
Journal:  Genomics       Date:  2002-08       Impact factor: 5.736

5.  Proteomics analysis of the centromere complex from HeLa interphase cells: UV-damaged DNA binding protein 1 (DDB-1) is a component of the CEN-complex, while BMI-1 is transiently co-localized with the centromeric region in interphase.

Authors:  Chikashi Obuse; Hua Yang; Naohito Nozaki; Shouhei Goto; Tuneko Okazaki; Kinya Yoda
Journal:  Genes Cells       Date:  2004-02       Impact factor: 1.891

6.  Identification of genes differentially expressed in mouse mammary epithelium transformed by an activated beta-catenin.

Authors:  Jean-Pierre Renou; Brian Bierie; Keiko Miyoshi; Yongzhi Cui; Jean Djiane; Moshe Reichenstein; Moshe Shani; Lothar Hennighausen
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

7.  Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes.

Authors:  Harry Dolstra; Björn de Rijke; Hanny Fredrix; Antonio Balas; Frans Maas; Frank Scherpen; Maria J Aviles; Jose L Vicario; Nico J Beekman; Ferry Ossendorp; Theo M de Witte; Elly van de Wiel-van Kemenade
Journal:  Eur J Immunol       Date:  2002-10       Impact factor: 5.532

8.  Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling.

Authors:  Yoshiki Akatsuka; Edus H Warren; Ted A Gooley; Anthony G Brickner; Ming-Tseh Lin; John A Hansen; Paul J Martin; David K Madtes; Victor H Engelhard; Toshitada Takahashi; Stanley R Riddell
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

9.  Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens.

Authors:  Yoshiki Akatsuka; Tetsuya Nishida; Eisei Kondo; Mikinori Miyazaki; Hirohumi Taji; Hiroatsu Iida; Kunio Tsujimura; Makoto Yazaki; Tomoki Naoe; Yasuo Morishima; Yoshihisa Kodera; Kiyotaka Kuzushima; Toshitada Takahashi
Journal:  J Exp Med       Date:  2003-05-27       Impact factor: 14.307

10.  A human minor histocompatibility antigen resulting from differential expression due to a gene deletion.

Authors:  Makoto Murata; Edus H Warren; Stanley R Riddell
Journal:  J Exp Med       Date:  2003-05-12       Impact factor: 14.307

View more
  42 in total

Review 1.  Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.

Authors:  Richard J O'Reilly; Tao Dao; Guenther Koehne; David Scheinberg; Ekaterina Doubrovina
Journal:  Semin Immunol       Date:  2010-05-26       Impact factor: 11.130

2.  The contributions of mass spectrometry to understanding of immune recognition by T lymphocytes.

Authors:  Victor H Engelhard
Journal:  Int J Mass Spectrom       Date:  2007-01-01       Impact factor: 1.986

3.  CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.

Authors:  Scott S Tykodi; Shoko Satoh; Janise D Deming; Jeffrey Chou; Richard Harrop; Edus H Warren
Journal:  J Immunother       Date:  2012-09       Impact factor: 4.456

Review 4.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 5.  Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia.

Authors:  Aaron E Foster; Malcolm K Brenner; Gianpietro Dotti
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

6.  Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Authors:  Tetsuya Nishida; Michael Hudecek; Ana Kostic; Marie Bleakley; Edus H Warren; David Maloney; Rainer Storb; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2009-06-30       Impact factor: 12.531

Review 7.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

Review 8.  Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.

Authors:  Xin Feng; Kwok Min Hui; Hashem M Younes; Anthony G Brickner
Journal:  Trends Immunol       Date:  2008-10-25       Impact factor: 16.687

9.  Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation.

Authors:  Persis P Wadia; Marc Coram; Randall J Armstrong; Michael Mindrinos; Atul J Butte; David B Miklos
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

10.  Two host factors regulate persistence of H7-specific T cells injected in tumor-bearing mice.

Authors:  Marie-Christine Meunier; Chantal Baron; Claude Perreault
Journal:  PLoS One       Date:  2009-01-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.